公开(公告)号：WO2008005511A2

公开(公告)日：2008-01-10

申请号：PCT/US2007/015530

申请日：2007-06-05

Applicant: INTERMUNE, INC. ,  ARRAY BIOPHARMA, INC. ,  BLATT, Lawrence M. ,  SEIWERT, Scott ,  BEIGELMAN, Leonid ,  KERCHER, Timothy ,  KENNEDY, April L. ,  ANDREWS, Steven W.

Inventor： BLATT, Lawrence M. ,  SEIWERT, Scott ,  BEIGELMAN, Leonid ,  KERCHER, Timothy ,  KENNEDY, April L. ,  ANDREWS, Steven W.

IPC: C07D231/56 ,  C07D403/14 ,  C07D471/04 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/437 ,  A61P31/14

CPC classification number: C07D403/14 ,  C07D231/56 ,  C07D471/04

Abstract: The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula (III), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Abstract translation: 实施方案提供了通式（I）的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式（II）的化合物以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式（III）的化合物以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

公开(公告)号：WO2017011776A1

公开(公告)日：2017-01-19

申请号：PCT/US2016/042576

申请日：2016-07-15

Applicant: ARRAY BIOPHARMA, INC.

Inventor： ANDREWS, Steven W. ,  BLAKE, James F. ,  CHICARELLI, Mark J. ,  GOLOS, Adam ,  HAAS, Julia ,  JIANG, Yutong ,  KOLAKOWSKI, Gabrielle R.

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00 ,  A61P29/00

CPC classification number: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/499 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D519/00

Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Abstract translation: 本文提供了通式I的化合物及其立体异构体及其药学上可接受的盐或溶剂化物，其中A，B，D，E，X 1，X 2，X 3和X 4具有说明书中给出的含义，其为RET的抑制剂 激酶，并且可用于治疗和预防可用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或病症。

公开(公告)号：WO2018136663A1

公开(公告)日：2018-07-26

申请号：PCT/US2018/014281

申请日：2018-01-18

Applicant: ARRAY BIOPHARMA, INC.

Inventor： ANDREWS, Steven W. ,  BLAKE, James F. ,  HAAS, Julia ,  JIANG, Yutong

IPC: C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  A61P35/00 ,  A61K31/506

Abstract: Provided herein are compounds of the Formula (I): and pharmaceutically acceptable salts or solvates thereof, where A, B, Y, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , n and m are as defined in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：WO2011029027A1

公开(公告)日：2011-03-10

申请号：PCT/US2010/047856

申请日：2010-09-03

Applicant: ARRAY BIOPHARMA INC. ,  ANDREWS, Steven W. ,  CONDROSKI, Kevin Ronald ,  DE MEESE, Lisa A. ,  FELL, Jay Bradford ,  FISCHER, John P. ,  LE HUEROU, Yvan ,  JOSEY, John A. ,  KOCH, Kevin ,  MIKNIS, Gregory F. ,  RODRIGUEZ, Martha E. ,  TOPALOV, George T. ,  WALLACE, Eli M. ,  XU, Rui

Inventor： ANDREWS, Steven W. ,  CONDROSKI, Kevin Ronald ,  DE MEESE, Lisa A. ,  FELL, Jay Bradford ,  FISCHER, John P. ,  LE HUEROU, Yvan ,  JOSEY, John A. ,  KOCH, Kevin ,  MIKNIS, Gregory F. ,  RODRIGUEZ, Martha E. ,  TOPALOV, George T. ,  WALLACE, Eli M. ,  XU, Rui

IPC: C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04

Abstract: Compounds of Formula I: and salts thereof in which R 1 , R 2 , R 2a , R 3 , n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

Abstract translation: 式I化合物及其盐，其中R 1，R 2，R 2a，R 3，n，X和环B具有本说明书中给出的含义，是mTOR的抑制剂，可用于治疗对抑制作用敏感的疾病 mTOR，如癌症。

公开(公告)号：WO2015175788A1

公开(公告)日：2015-11-19

申请号：PCT/US2015/030795

申请日：2015-05-14

Applicant: ARRAY BIOPHARMA INC.

Inventor： ALLEN, Shelley ,  ANDREWS, Steven W. ,  BAER, Brian ,  CRANE, Zackary ,  LIU, Weidong ,  WATSON, Daniel John

IPC: C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  A61K31/4155

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K45/06 ,  C07D207/16 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.

Abstract translation: 提供作为TrkA激酶抑制剂的化合物（I）或其药学上可接受的盐，可用于治疗可用TrkA激酶抑制剂如疼痛，癌症，炎症和炎性疾病，神经变性疾病治疗的疾病 某些传染病，干燥综合征，子宫内膜异位症，糖尿病性周围神经病变，前列腺炎，骨盆疼痛综合征，与骨重塑调节失调有关的疾病，以及由结缔组织生长因子异常信号引起的疾病。

公开(公告)号：WO2017075107A9

公开(公告)日：2017-05-04

申请号：PCT/US2016/058951

申请日：2016-10-26

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE ,  LOXO ONCOLOGY, INC. ,  ARRAY BIOPHARMA INC.

Inventor： ANDREWS, Steven W. ,  KOLAKOWSKI, Gabrielle R. ,  DOEBELE, Robert C. ,  NANDA, Nisha ,  BILENKER, Josh H. ,  BLAKE, James F. ,  BRANDHUBER, Barbara J. ,  ZHAO, Qian

IPC: A61K31/5025 ,  A61K31/519 ,  C12Q1/68 ,  A61P35/00 ,  G01N33/574

Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.

公开(公告)号：WO2017070708A1

公开(公告)日：2017-04-27

申请号：PCT/US2016/058549

申请日：2016-10-24

Applicant: ARRAY BIOPHARMA, INC.

Inventor： ANDREWS, Steven W. ,  BLAKE, James F. ,  COOK, Adam ,  GUNAWARDANA, Indrani W. ,  HUNT, Kevin W. ,  METCALF, Andrew T. ,  MORENO, David ,  REN, Li ,  TANG, Tony P.

IPC: C07D401/14 ,  C07D403/14 ,  A61K31/444 ,  A61P35/00

CPC classification number: C07D403/14 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D413/14 ,  C12Q1/6886 ,  G01N33/574

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R 1 , R 2 , R 3 , Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

Abstract translation: 本文提供通式I的化合物及其立体异构体和药学上可接受的盐或溶剂化物，其中X，R 1，R 2， R 3和R 3具有在说明书中给出的含义，它们是FGFR1，FGFR2，FGFR3和/或FGFR4的抑制剂，并且可用于治疗和预防可以是 用FGFR抑制剂治疗，包括由FGFR1，FGFR2，FGFR3和/或FGFR4介导的疾病或病症。

公开(公告)号：WO2007015824A3

公开(公告)日：2007-02-08

申请号：PCT/US2006/027738

申请日：2006-07-17

Applicant: INTERMUNE, INC. ,  ARRAY BIOPHARMA INC. ,  SEIWERT, Scott D. ,  BLATT, Lawrence M. ,  ANDREWS, Steven W. ,  MARTIN, Pierre ,  SCHUMACHER, Andreas ,  BARNETT, Bradley, R. ,  EARY, Todd, C. ,  KAUS, Robert ,  KERCHER, Timothy ,  LIU, Weidong ,  LYON, Michael ,  NICHOLS, Paul ,  WANG, Bin ,  SAMMAKIA, Tarek ,  KENNEDY, April ,  JIANG, Yutong

Inventor： SEIWERT, Scott D. ,  BLATT, Lawrence M. ,  ANDREWS, Steven W. ,  MARTIN, Pierre ,  SCHUMACHER, Andreas ,  BARNETT, Bradley, R. ,  EARY, Todd, C. ,  KAUS, Robert ,  KERCHER, Timothy ,  LIU, Weidong ,  LYON, Michael ,  NICHOLS, Paul ,  WANG, Bin ,  SAMMAKIA, Tarek ,  KENNEDY, April ,  JIANG, Yutong

IPC: C07K5/12 ,  A61K38/00 ,  A61P31/14 ,  C07D209/44 ,  C07C231/02 ,  C07C269/00 ,  C07D207/16

Abstract: The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

公开(公告)号：EP3458456B1

公开(公告)日：2020-11-25

申请号：EP17726442.1

申请日：2017-05-18

Applicant: Loxo Oncology, Inc. ,  Array Biopharma Inc.

Inventor： REYNOLDS, Mark ,  EARY, Charles Todd ,  SPENCER, Stacey ,  JUENGST, Derrick ,  HACHE, Bruno ,  JIANG, Yutong ,  HAAS, Julia ,  ANDREWS, Steven W.

IPC: C07D487/04 ,  A61K31/5025 ,  A61P35/00 ,  A61P43/00

公开(公告)号：EP3322706A1

公开(公告)日：2018-05-23

申请号：EP16741825.0

申请日：2016-07-15

Applicant: Array Biopharma, Inc.

Inventor： ANDREWS, Steven W. ,  BLAKE, James F. ,  CHICARELLI, Mark J. ,  GOLOS, Adam ,  HAAS, Julia ,  JIANG, Yutong ,  KOLAKOWSKI, Gabrielle R.

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00 ,  A61P29/00

Abstract: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.